- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to medical supply chain, including supply chain safety.
- Issues related to drug pricing including drug negotiation.
- Issues related to Inflation Reduction Act.
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Issues relating to the impact of prescription drug negotiation on generic drugs and biosimilars.
Issues related to Medicare Part D reform.
Issues related to drug shortages
Generic Drug User Fee Amendments (GDUFA).
Duration: February 1, 2016
to
present
General Issues: Health Issues , Medicare/Medicaid , Pharmacy , Trade (Domestic & Foreign) , Taxation/Internal Revenue Code , Budget/Appropriations , Indian/Native American Affairs
Spending: about $1,500,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Brian Sutter Staff Dir. W&M Health subcommittee, Chairman Dave Camp April'13-Dec'14. Professional Staff, W&M Health subcommittee, Chairman Dave Camp, Jan'11-April'13. Leg Dir. Rep Dave Camp, May'08-Jan'11. Leg Asst Rep Dave Camp, Feb'03-May'08. Staff Ast July'02
Staff Dir. W&M Health subcommittee, Chairman Dave Camp April'13-Dec'14. Professional Staff, W&M Health subcommittee, Chairman Dave Camp, Jan'11-April'13. Leg Dir. Rep Dave Camp, May'08-Jan'11. Leg Asst Rep Dave Camp, Feb'03-May'08. Staff Ast July'02
David Stratton Edwards Staff Assistant for Rep. John Sullivan Nov. 2003 - Aug. 2006. Legislative Counsel for Rep. Tom Cole Aug. 2010 - Mar. 2015
Staff Assistant for Rep. John Sullivan Nov. 2003 - Aug. 2006. Legislative Counsel for Rep. Tom Cole Aug. 2010 - Mar. 2015
Staff Assistant for Rep. John Sullivan Nov. 2003 - Aug. 2006. Legislative Counsel for Rep. Tom Cole Aug. 2010 - Mar. 2015.
William Steve Southerland William Steve Southerland, II served as the U.S. Representative for Florida's 2nd congressional district from 2011 to 2015.
Tom Wharton Health Legislative Assistant - Senator Joe Lieberman. May 2011 - June 2012
Senior Legislative Assistant - Congressman Dan Boren. July 2008 - June 2011
Health Legislative Assistant - Senator Joe Lieberman. May 2011 - June 2012 Senior Legislative Assistant - Congressman Dan Boren. July 2008 - June 2011
Willian Steve Southerland William Steve Southerland, II served as the U.S. Representative for Florida's 2nd congressional district from 2011 to 2015.
Willliam Steve Southerland William Steve Southerland, II served as the U.S. Representative for Florida's 2nd congressional district from 2011 to 2015.
Emily Wilkinson Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19)
Emily Wilkinson-Holland Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19)
Christopher Davis Staff Assistant, Legislative Assistant, Senior Legislative Assistant, and Legislative Director - Rep. Rick Boucher (2006-2011)
Staff Assistant, Legislative Assistant, Senior Legislative Assistant, and Legislative Director - Rep. Rick Boucher (2006-2011).
Emily Holland Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19)
David Jory n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on April 21.
Original Filing: 301568816.xml
Lobbying Issues
- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to medical supply chain, including supply chain safety.
- Issues related to drug pricing including drug negotiation.
- Issues related to Inflation Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Issues relating to the impact of prescription drug negotiation on generic drugs and biosimilars.
Issues related to Medicare Part D reform.
Issues related to drug shortages
Agencies Lobbied
U.S. Senate
Lobbying Issues
Generic Drug User Fee Amendments (GDUFA).
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $40,000. The report was filed on Jan. 19.
Original Filing: 301533151.xml
Lobbying Issues
- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to medical supply chain, including supply chain safety.
- Issues related to drug pricing including drug negotiation.
- Issues related to Inflation Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Issues relating to the impact of prescription drug negotiation on generic drugs and biosimilars.
Issues related to Medicare Part D reform.
Issues related to drug shortages
Agencies Lobbied
U.S. Senate
Lobbying Issues
Generic Drug User Fee Amendments (GDUFA).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $40,000. The report was filed on Oct. 23, 2023.
Original Filing: 301517200.xml
Lobbying Issues
- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to medical supply chain, including supply chain safety.
- Issues related to drug pricing including drug negotiation.
- Issues related to Inflation Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Issues relating to the impact of prescription drug negotiation on generic drugs and biosimilars.
Issues related to Medicare Part D reform.
Issues related to drug shortages
Agencies Lobbied
U.S. Senate
Lobbying Issues
Generic Drug User Fee Amendments (GDUFA).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $40,000. The report was filed on July 20, 2023.
Original Filing: 301487350.xml
Lobbying Issues
- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to medical supply chain, including supply chain safety.
- Issues related to drug pricing including drug negotiation.
- Issues related to Inflation Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Issues relating to the impact of prescription drug negotiation on generic drugs and biosimilars.
Issues related to Medicare Part D reform.
Issues related to drug shortages
Agencies Lobbied
U.S. Senate
Lobbying Issues
Generic Drug User Fee Amendments (GDUFA).
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $40,000. The report was filed on April 21, 2023.
Original Filing: 301468252.xml
Lobbying Issues
- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to medical supply chain, including supply chain safety.
- Issues related to drug pricing including drug negotiation.
- Issues related to Inflation Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Issues relating to the impact of prescription drug negotiation on generic drugs and biosimilars.
Issues related to Medicare Part D reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Generic Drug User Fee Amendments (GDUFA).
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $40,000. The report was filed on Jan. 20, 2023.
Original Filing: 301438136.xml
Lobbying Issues
- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to medical supply chain, including supply chain safety.
- Issues related to drug pricing including drug negotiation.
- Issues related to Inflation Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Issues relating to the impact of prescription drug negotiation on generic drugs and biosimilars.
Issues related to Medicare Part D reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Generic Drug User Fee Amendments (GDUFA)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $40,000. The report was filed on Oct. 20, 2022.
Original Filing: 301416222.xml
Lobbying Issues
- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to medical supply chain, including supply chain safety.
- Issues related to drug pricing including drug negotiation
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Issues relating to the impact of prescription drug negotiation on generic drugs and biosimilars.
Issues related to Medicare Part D reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Buy American.
Issues surrounding the generic drug and biosimilar user fee agreements.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Generic Drug User Fee Amendments (GDUFA)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) in Q32022 on Oct. 20, 2022.
Original Filing: 301418823.xml
Lobbying Issues
- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to medical supply chain, including supply chain safety.
- Issues related to drug pricing including drug negotiation.
- Issues related to Inflation Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Issues relating to the impact of prescription drug negotiation on generic drugs and biosimilars.
Issues related to Medicare Part D reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Buy American.
Issues surrounding the generic drug and biosimilar user fee agreements.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Generic Drug User Fee Amendments (GDUFA)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) in Q32022 on Oct. 20, 2022.
Original Filing: 301416343.xml
Lobbying Issues
- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to medical supply chain, including supply chain safety.
- Issues related to drug pricing including drug negotiation.
- Issues related to Inflation Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Issues relating to the impact of prescription drug negotiation on generic drugs and biosimilars.
Issues related to Medicare Part D reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Buy American.
Issues surrounding the generic drug and biosimilar user fee agreements.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Generic Drug User Fee Amendments (GDUFA)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $40,000. The report was filed on July 20, 2022.
Original Filing: 301393817.xml
Lobbying Issues
- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to medical supply chain, including supply chain safety.
- Issues related to drug pricing including drug negotiation
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Issues relating to the impact of prescription drug negotiation on generic drugs and biosimilars.
Issues related to Medicare Part D reform
Issues surrounding the generic drug and biosimilar user fee agreements.
Issues surrounding the generic drug and biosimilar user fee agreements.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Buy American.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Generic Drug User Fee Amendments (GDUFA)
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $40,000. The report was filed on April 20, 2022.
Original Filing: 301365632.xml
Lobbying Issues
- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to coronavirus, including supply chain safety.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Issues relating to the impact of prescription drug negotiation on generic drugs and biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Buy American.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Generic Drug User Fee Amendments (GDUFA)
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $40,000. The report was filed on Jan. 21, 2022.
Original Filing: 301339223.xml
Lobbying Issues
- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to coronavirus, including supply chain safety.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Issues relating to the impact of prescription drug negotiation on generic drugs and biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Buy American.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2021
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $40,000. The report was filed on Oct. 18, 2021.
Original Filing: 301301957.xml
Lobbying Issues
- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to coronavirus, including supply chain safety.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Buy American.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2021
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $40,000. The report was filed on Oct. 13, 2021.
Original Filing: 301298407.xml
Lobbying Issues
- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to coronavirus, including supply chain safety.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Buy American.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $40,000. The report was filed on April 20, 2021.
Original Filing: 301263040.xml
Lobbying Issues
- Issues relating to the labeling of generic drugs.
- Issues relating to the 180 day exclusivity for generics.
- Issues related to coronavirus, including supply chain safety.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Buy American.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2020
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $40,000. The report was filed on Jan. 20, 2021.
Original Filing: 301240704.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- Issues relating to the Lower Health Care Costs Act, including 180 day exclusivity for generics.
- Issues related to coronavirus, including supply chain safety.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Buy American.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2020
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222896.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- Issues relating to the Lower Health Care Costs Act, including 180 day exclusivity for generics.
- Issues related to coronavirus, including supply chain safety.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Buy American.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2020
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301200410.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- Issues relating to the Lower Health Care Costs Act, including 180 day exclusivity for generics.
- Issues related to coronavirus, including supply chain safety.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to coverage of generics and biosimilars as part of USMCA. Issues related to Buy American.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2020
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on April 17, 2020.
Original Filing: 301171057.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- Issues relating to the Lower Health Care Costs Act, including 180 day exclusivity for generics.
- Issues related to coronavirus, including supply chain safety.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to coverage of generics and biosimilars as part of USMCA. Issues related to Buy American.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2019
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on Jan. 20, 2020.
Original Filing: 301123341.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- FAST Generics Act / CREATES Act of 2017 concerning REMS
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform concerning Border Adjustment Tax
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues relating to coverage of generics and biosimilars as part of USMCA
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2019
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on Oct. 17, 2019.
Original Filing: 301068242.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- FAST Generics Act / CREATES Act of 2017 concerning REMS
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Issues related to Part D coverage of generic drugs, including Part D redesign.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform concerning Border Adjustment Tax
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues relating to coverage of genetics and biosimilars as part of USMCA
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2019
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on July 22, 2019.
Original Filing: 301057023.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- FAST Generics Act / CREATES Act of 2017 concerning REMS
- Issues related to H.R. 1628, the American Health Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform concerning Border Adjustment Tax
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues relating to coverage of genetics and biosimilars as part of USMCA
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2019
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on April 19, 2019.
Original Filing: 301031916.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- FAST Generics Act / CREATES Act of 2017 concerning REMS
- Issues related to H.R. 1628, the American Health Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform concerning Border Adjustment Tax
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues relating to coverage of genetics and biosimilars as part of USMCA
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2018
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on Jan. 20, 2019.
Original Filing: 301011110.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- FAST Generics Act / CREATES Act of 2017 concerning REMS
- Issues related to H.R. 1628, the American Health Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform concerning Border Adjustment Tax
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues relating to coverage of genetics and biosimilars as part of USMCA
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2018
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on Oct. 11, 2018.
Original Filing: 300984331.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- FAST Generics Act / CREATES Act of 2017 concerning REMS
- Issues related to H.R. 1628, the American Health Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform concerning Border Adjustment Tax
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2018
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on July 20, 2018.
Original Filing: 300977815.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- FAST Generics Act / CREATES Act of 2017 concerning REMS
- Issues related to H.R. 1628, the American Health Care Act.
- Issues related to H.R. 1625, the Consolidated Appropriations Act of 2018
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform concerning Border Adjustment Tax
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2018
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on April 19, 2018.
Original Filing: 300951669.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- FAST Generics Act / CREATES Act of 2017 concerning REMS
- Issues related to H.R. 1628, the American Health Care Act.
- Issues related to H.R. 1625, the Consolidated Appropriations Act of 2018
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
Issues related to the Medicare low-income subsidy.
Issues related to the cost of prescription drugs.
Issues pertaining to coverage and reimbursement of biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform concerning Border Adjustment Tax
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2017
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on Jan. 22, 2018.
Original Filing: 300935118.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- House 21st Century CURES legislation (including Senate companion bill(s))
- FAST Generics Act / CREATES Act of 2016 concerning REMS
- Issues related to H.R. 1628, the American Health Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
- Issues related to the Medicare low-income subsidy.
- Issues related to the cost of prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to the labeling of generic drugs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform concerning Border Adjustment Tax
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Patent dispute involving Indian tribe.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Indian/Native American Affairs
3rd Quarter, 2017
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on Oct. 19, 2017.
Original Filing: 300910825.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- House 21st Century CURES legislation (including Senate companion bill(s))
- FAST Generics Act / CREATES Act of 2016 concerning REMS
- Issues related to H.R. 1628, the American Health Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
- Issues related to the Medicare low-income subsidy.
- Issues related to the cost of prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to the labeling of generic drugs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform concerning Border Adjustment Tax
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Patent dispute involving Indian tribe.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Indian/Native American Affairs
2nd Quarter, 2017
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on July 20, 2017.
Original Filing: 300896255.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- House 21st Century CURES legislation (including Senate companion bill(s))
- FAST Generics Act / CREATES Act of 2016 concerning REMS
- Issues related to H.R. 1628, the American Health Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
- Issues related to the Medicare low-income subsidy.
- Issues related to the cost of prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to the labeling of generic drugs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform concerning Border Adjustment Tax
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Association for Accessible Medicines (Formerly Generic Pharmaceutical Assoc.) , earning $50,000. The report was filed on April 20, 2017.
Original Filing: 300876940.xml
Lobbying Issues
- Issues relating to bioequivalence and related administrative procedures.
- Issues relating to prescription drug abuse.
- Issues relating to the labeling of generic drugs.
- House 21st Century CURES legislation (including Senate companion bill(s))
- FAST Generics Act / CREATES Act of 2016 concerning REMS
- Issues related to H.R. 1628, the American Health Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
- Issues related to the Medicare low-income subsidy.
- Issues related to the cost of prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to the labeling of generic drugs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform concerning Border Adjustment Tax
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Generic Pharmaceutical Association (GPhA) , earning $50,000. The report was filed on Jan. 20, 2017.
Original Filing: 300853386.xml
Lobbying Issues
-Issues relating to bioequivalence and related administrative procedures.
-Issues relating to prescription drug abuse.
-Issues relating to the labeling of generic drugs.
-House 21st Century CURES legislation (including Senate companion bill(s))
-S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641.
- H.R.2841 - FAST Generics Act / S.3056 - CREATES Act of 2016 concerning REMS
Agencies Lobbied
U.S. Senate
Lobbying Issues
-Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
-Issues related to the Medicare low-income subsidy.
-Issues related to the cost of prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to the labeling of generic drugs.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Generic Pharmaceutical Association (GPhA) , earning $50,000. The report was filed on Oct. 20, 2016.
Original Filing: 300838939.xml
Lobbying Issues
-Issues relating to bioequivalence and related administrative procedures.
-Issues relating to prescription drug abuse.
-Issues relating to the labeling of generic drugs.
-House 21st Century CURES legislation (including Senate companion bill(s))
-S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641.
- H.R.2841 - FAST Generics Act / S.3056 - CREATES Act of 2016 concerning REMS
Agencies Lobbied
U.S. Senate
Lobbying Issues
-Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
-Issues related to the Medicare low-income subsidy.
-Issues related to the cost of prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to the labeling of generic drugs.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Generic Pharmaceutical Association (GPhA) , earning $50,000. The report was filed on July 20, 2016.
Original Filing: 300821169.xml
Lobbying Issues
-Issues relating to bioequivalence and related administrative procedures.
-Issues relating to prescription drug abuse.
-Issues relating to the labeling of generic drugs.
-House 21st Century CURES legislation (including Senate companion bill(s))
-S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641.
Agencies Lobbied
U.S. Senate
Lobbying Issues
-Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
-Issues related to the Medicare low-income subsidy.
-Issues related to the cost of prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to the labeling of generic drugs.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Generic Pharmaceutical Association (GPhA) in Q12016 on June 14, 2016.
Original Filing: 300805947.xml
Lobbying Issues
-Issues relating to bioequivalence and related administrative procedures.
-Issues relating to prescription drug abuse.
-Issues relating to the labeling of generic drugs.
-House 21st Century CURES legislation (including Senate companion bill(s))
-S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641.
Agencies Lobbied
U.S. Senate
Lobbying Issues
-Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
-Issues related to the Medicare low-income subsidy.
-Issues related to the cost of prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to the labeling of generic drugs.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Generic Pharmaceutical Association (GPhA) , earning $30,000. The report was filed on April 15, 2016.
Original Filing: 300791945.xml
Lobbying Issues
-Issues relating to bioequivalence and related administrative procedures.
-Issues relating to prescription drug abuse.
-Issues relating to the labeling of generic drugs.
-House 21st Century CURES legislation (including Senate companion bill(s))
-S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641.
Agencies Lobbied
U.S. Senate
Lobbying Issues
-Provisions from the Bipartisan Budget Act of 2015 concerning the Medicaid rebate program.
-Issues related to the Medicare low-income subsidy.
-Issues related to the cost of prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to the labeling of generic drugs.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
Capitol Hill Consulting Group filed a lobbying registration on March 11, 2016 to represent Generic Pharmaceutical Association (GPhA), effective Feb. 1, 2016.
Original Filing: 300787326.xml
Issue(s) they said they’d lobby about: Issues related to the approval of generic drugs, FDA Labeling, Regulation of Biosimilars, Medicare and Medicaid Reimbursement, Agriculture Appropriations (FDA) .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...